Skip to main content
. 2020 Jun 18;13(10):100817. doi: 10.1016/j.tranon.2020.100817

Fig. 4.

Fig. 4

In vitro sensitivity to main therapeutics and ibrutinib in primary BCP-ALL samples. (A–D) In vitro sensitivity of five primary BCP-ALL samples measured in MTT assays to 0.78 μg/mL vincristine (A), 0.488 μg/mL prednisolone (B), 0.031 μg/mL daunorubicin (C) and 0.08 IU/mL asparaginase (D). Either as a single agent (black bars) or in combination with 4 μM ibrutinib (grey bars). Primary cells were TCF3-PBX1 positive (TP+, BCP-ALL #7 and #8), B-Other (BO, BCP-ALL #9) or BCR-ABL1-like (BA-like, BCP-ALL #10 and #11). Error and average survival relative to survival with no drug (for single agent) or survival with 4 μM ibrutinib (drug combination testing). Survival with 4 μM ibrutinib as a single agent ranged between 66 and 103% compared to survival of placebo treated cells.